Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thailand To Allow Generic Of Taxotere Under CL Policy

This article was originally published in PharmAsia News

Executive Summary

Thailand's drug authority says it intends to use its compulsory licensing policy to import a generic of the Sanofi Aventis breast cancer drug Taxotere (docetaxel). The Government Pharmaceutical Organisation says it also will follow through on plans to use its CL policy to import two other cancer generics, for Roche/OSI Pharmaceuticals' Tarceva (erlotinib hydrochloride) and the Novartis drug Femara (letrozole). The Taxotere generic is to be supplied by India's Dabur Pharma, which is expected to deliver its first thousand doses soon, at 1 percent of the Sanofi price. (Click here for more

You may also be interested in...

Thailand’s Public Health Minister Asked To Step Down For Failing To Report Shareholdings

PERTH, Australia - Thailand's Public Health Minister Chaiya Sasomsab may have to step down from his post after failing to report his wife's shareholdings in a company, according to the Bangkok Post

IQVIA: US Out-Of-Pocket Drug Costs Stable, But Overall Spending Is Higher

New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.

Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts